| Literature DB >> 32690111 |
Siphokazi Sinethemba Mtwebana1, Earl Prinsloo2.
Abstract
OBJECTIVE: Target specific small molecule inhibitors has driven signaling pathway discovery and are used as common positive controls in drug discovery screens. During a biophysical screen, using surface plasmon resonance spectroscopy, of a novel small molecule library for the Signal Transducer and Activator of Transcription 3 Src Homology 2 (STAT3-SH2) low molecular weight interactors we evaluated commercial inhibitors S3I-201 and 5,15-diphenylporphyrin (5, 15-DPP) as positive controls.Entities:
Keywords: JAK-STAT3; STAT3; Surface plasmon resonance
Mesh:
Substances:
Year: 2020 PMID: 32690111 PMCID: PMC7372768 DOI: 10.1186/s13104-020-05189-w
Source DB: PubMed Journal: BMC Res Notes ISSN: 1756-0500
Fig. 1FTIR spectra for structural integrity of recombinant STAT3 (in presence and absence of Mg2 + containing buffer) and thermally denatured protein. Spectra represent Amide II (1500–1600 cm−1) and Amide I (1600–1700 cm−1). Divalent cations have been shown to promote homodimerization of STAT3 [10], this appears to have resulted in an altered Amide I peak
Fig. 2Sensorgrams showing comparative binding of immobilized recombinant STAT3 to commercial inhibitors (a) S3I-201 at 80 µM (b) 5, 15-DPP at 80 µM and (c) 5,15-DPP at 100 µM. Sensorgrams are representative of 3 flow rates as indicated